By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

DelMar Pharmaceuticals 

999 West Broadway
Suite 720
  British Columbia  V5Z 1K5  Canada
Phone: 1-604-629-5989 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
DelMar Pharma Collaborates With Duke University To Explore VAL-083 As A Front-Line Treatment For Glioblastoma Multiforme 4/25/2017 7:26:37 AM
DelMar Pharma Announces Closing Of $9,000,000 Public Offering Of Common Stock And Warrants 4/21/2017 7:21:08 AM
DelMar Pharma Announces Pricing Of $9,000,000 Public Offering Of Common Stock And Warrants 4/13/2017 11:03:52 AM
DelMar Pharma Provides VAL-083 Updates From The Ongoing AACR Annual Meeting 4/5/2017 7:54:35 AM
DelMar Pharma Announces Second Quarter Fiscal Year 2017 Financial Results 2/13/2017 8:30:53 AM
DelMar Pharma Announces Dosing Of The First Patient In Phase Two Clinical Trial Of VAL-083 For MGMT-Unmethylated Recurrent Glioblastoma Multiforme (GBM) 2/13/2017 7:01:45 AM
DelMar Pharma Release: Company And MD Anderson Cancer Center Initiate New Phase Two Clinical Trial Of VAL-083 For MGMT-Unmethylated Recurrent Glioblastoma Multiforme (GBM) 1/25/2017 9:52:26 AM
DelMar Pharma Receives Additional Non-Dilutive Funding From The Government Of Canada To Support Expanded Research With Lead Product Candidate VAL-083 1/9/2017 9:30:51 AM
DelMar Pharma Receives Notice Of Allowance From The US Patent And Trademark Office For Key Patent For VAL-083 12/14/2016 6:52:06 AM
DelMar Pharma Delivers An Address And Presents An Overview Of Upcoming GBM Trials With VAL-083 At The CNS Anticancer Drug Discovery Development Conference And Society For NeuroOncology Annual Meeting 11/21/2016 9:09:29 AM
12345678910...
//-->